AstraZeneca PLC’s Farxiga/Forxiga (dapagliflozin) has become the first SGLT2 inhibitor to show a reduction in the risk of cardiovascular death or worsening of heart failure in patients with reduced ejection fraction heart failure (HFrEF), with or without type 2 diabetes, when added to the standard of care.
The positive results, from the DAPA-HF study, should give a boost to dapagliflozin, whose sales grew by 14% to reach...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)